Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19227370 | 1.00 | ALDH1A1 (0.45) | ALDH1A1CYP3A4 | |
| SCHEMBL8666695 | 0.94 | ALDH1A1 (0.41) | ALDH1A1CYP3A4 | |
| SCHEMBL3407607 | 0.80 | APLNR (0.39) | ALDH1A1 | |
| SCHEMBL23837215 | 0.75 | ALDH1A1 (0.60) | ALDH1A1CYP3A4 | |
| SCHEMBL11041976 | 0.75 | ALDH1A1 (0.60) | ALDH1A1CYP3A4 | |
| SCHEMBL12019112 | 0.74 | ALDH1A1 (0.65) | ALDH1A1CYP3A4 | |
| SCHEMBL9418103 | 0.73 | ALDH1A1 (0.44) | ALDH1A1CYP3A4 | |
| SCHEMBL7043819 | 0.73 | ALDH1A1 (0.44) | ALDH1A1CYP3A4 | |
| SCHEMBL7753405 | 0.73 | ALDH1A1 (0.50) | ALDH1A1CYP3A4 | |
| SCHEMBL9974620 | 0.72 | ALDH1A1 (0.42) | ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509547-B2 | Synthesis of linear polyoxazolidinones using uretdiones as diisocyanate component | BASF SE (DE) | 2025-12-30 | — | — | US | claimed |
| US-20230348657-A1 | SYNTHESIS OF LINEAR POLYOXAZOLIDINONES USING URETDIONES AS DIISOCYANATE COMPONENT | BASF SE (DE) | 2023-11-02 | — | — | US | claimed |
| US-11766511-B2 | Antithrombogenic hollow fiber membranes and filters | INTERFACE BIOLOGICS, INC. (CA) | 2023-09-26 | — | — | US | claimed |
| EP-4185626-A1 | SYNTHESIS OF LINEAR POLYOXAZOLIDINONES USING URETDIONES AS DIISOCYANATE COMPONENT | BASF SE (DE) | 2023-05-31 | — | — | EP | claimed |
| US-11427671-B2 | Method for the production of thermoplastic polyoxazolidinone polymers | COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) | 2022-08-30 | — | — | US | claimed |
| EP-3873961-B1 | METHOD FOR THE PRODUCTION OF THERMOPLASTIC POLYOXAZOLIDINONE POLYMERS | COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) | 2022-08-17 | — | — | EP | claimed |
| US-11370874-B2 | Method for the production of thermoplastic polyoxazolidone polymers | COVESTRO DEUTSCHLAND AG (DE) | 2022-06-28 | — | — | US | claimed |
| EP-3873962-B1 | METHOD FOR THE PRODUCTION OF THERMOPLASTIC POLYOXAZOLIDINONE POLYMERS | COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) | 2022-05-18 | — | — | EP | claimed |
| EP-3681924-B1 | METHOD FOR THE PRODUCTION OF THERMOPLASTIC POLYOXAZOLIDINONE POLYMERS | COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) | 2022-05-18 | — | — | EP | claimed |
| US-11319398-B2 | Method for the production of polyoxazolidinone polymer compounds | COVESTRO DEUTSCHLAND AG (DE) | 2022-05-03 | — | — | US | claimed |
| EP-2295132-A1 | Antithrombogenic hollow fiber membranes, potting material and blood tubing | Interface Biologics Inc. (CA) | 2011-03-16 | — | — | EP | claimed |
| EP-2102258-A1 | SURFACE MODIFYING MACROMOLECULES WITH HIGH DEGRADATION TEMPERATURES AND USES THEREOF | Interface Biologics Inc. (CA) | 2009-09-23 | — | — | EP | claimed |
| US-20080228253-A1 | Surface modifying macromolecules with high degradation temperatures and uses thereof | Evonik Canada Inc. (CA) | 2008-09-18 | — | — | US | claimed |
| WO-2008076345-A1 | SURFACE MODIFYING MACROMOLECULES WITH HIGH DEGRADATION TEMPERATURES AND USES THEREOF | INTERFACE BIOLOGICS INC. (CA) | 2008-06-26 | — | — | WO | claimed |
| US-5032664-A | Process for the production of segmented polyurethane urea elastomer solutions and filaments and films thereof | BAYER AKTIENGESELLSCHAFT (DE) | 1991-07-16 | — | — | US | claimed |
| EP-0421214-A2 | Process for the preparation of segmented polyurethane-urea-elastomer solutions, as well as the fibres and films obtained in this way | BAYER AG (DE) | 1991-04-10 | — | — | EP | claimed |
| US-4918148-A | IMPROVED FLOWABILITY, MOLD RELEASE AND-OR NOTCHED IMPACT STRENGTH | BAYER AKTIENGESELLSCHAFT (DE) | 1990-04-17 | — | — | US | claimed |
| US-RE31389-E | DIALYSIS; BLOOD FILTRATION | CASCHEM, INC. (US) | 1983-09-20 | — | — | US | claimed |
| EP-0000963-B1 | ISOCYANURATES CONTAINING BLOCKED ISOCYANATE GROUPS, AND PROCESS FOR THEIR PREPARATION | CHEMISCHE WERKE HÜLS AG (DE) | 1982-06-23 | — | — | EP | claimed |
| US-4224164-A | Non-wicking polyurethane casting systems | NL INDUSTRIES, INC. (US) | 1980-09-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509547-B2 | Synthesis of linear polyoxazolidinones using uretdiones as diisocyanate component | BMP1, BMP4, PBRM1 | ALDH1A1 1995/4885CYP3A4 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.